Monoclonal antibodies to anthrax protective antigen

ABSTRACT

The characterization and isolation of F20G75, F20G76 and F20G77, anti-PA monoclonal antibodies which also have neutralizing activities is described. The monoclonal antibodies may be used as a pharmaceutical composition for treating individuals suspected of or at risk of or having a  Bacillus anthracis  infection. The monoclonal antibodies bind to a specific region comprising amino acids 311-316 of PA, ASFFDI or a larger fragment comprising amino acids 301-330 of PA, SEVHGNAEVHASFFDIGSSVSAGFSNSNSS. Vaccines comprising these peptides may be used to immunize individuals against  Bacillus anthracis  infection.

PRIOR APPLICATION INFORMATION

This application claims the benefit of U.S. Provisional Application60/800,831, filed May 17, 2006.

FIELD OF THE INVENTION

The invention relates to vaccines for Bacillus anthracis infections.

BACKGROUND OF THE INVENTION

Anthrax is a well-known infectious disease caused by a Gram-positivebacterium, Bacillus anthracis. There are three types of anthraxinfections: cutaneous, gastrointestinal and inhalation. Inhalationanthrax generally occurs after an incubation time of 1-6 days. After theincubation period, a non-specific flu-like illness ensues for 1-3 daysfollowed by a brief intervening period of improvement. Unfortunately,rapid deterioration follows and death is universal in untreated cases.

Airborne anthrax has long been concerned a major bioterror threat and ithas recently been shown that anthrax can be aerosolized and transmittedby mail.

The causative agent of anthrax, Bacillus anthracis, expresses threemajor extracellular toxin protein components, encoded on its large pXO1plasmid (Okinaka et al., 1999). Protective antigen (PA) combines witheither lethal factor (LF) or edema factor (EF) to form a functionalbinary toxin (reviewed in Abrami et al., 2005). PA in combination withLF causes death in experimental animals (Smith and Keppie, 1954, Nature173: 869-870) while PA in combination with EF causes edema in the skinof experimental animals (Stanley and Smith, 1961, J Gen Microbiol 26:49-66). While none of the proteins is individually toxic, PA combineswith either LF or EF to form one of two binary toxins. PA binds to oneof two cellular receptors, TEM8 (Bradley et al., 2001; Liu and Leppla,2003) or CMG2 (Scobie et al., 2003). Upon receptor binding, the 83 kDaPA (PA83) is cleaved at a specific sequence by furin or a furin-likeprotease, releasing a 20 kDa N-terminal fragment (PA20) while leaving a63 kDa C-terminal fragment (PA63) bound to the receptor (Singh et al.,1989; Molloy et al., 1992). An LF binding site on PA63 is simultaneouslyexposed via this cleavage event (Novak et al., 1992). Spontaneousheptamerization of the PA:receptor complex occurs (Milne et al., 1994),allowing competitive, high affinity binding by EF or LF (Cunningham etal., 2002; Mogridge et al., 2002), followed by internalization of thetoxin:receptor complex via clathrin-mediated endocytosis (Abrami et al.,2003). Acidification of the endosome produces structural rearrangementsin the PA prepore heptamer, leading to pore formation and membraneinsertion (Lacy et al., 2004; Santelli et al., 2004), and subsequentrelease of LF and/or EF into the cytosol (reviewed in Abrami et al.,2005).

PA is the primary antigenic determinant in currently licensed humananthrax vaccines (Turnbull et al., 1986; Leppla et al., 2002; Baillie etal., 2004; Adams et al., 2005). Several recent model studies demonstratethat a strong humoral response to PA contributes to a protective immuneresponse to anthrax (Miller et al., 1998; Pitt et al., 2001; Reuveny etal., 2001; Little et al., 2004), and several regions that serve astargets for neutralizing monoclonal antibodies have been identified(Little et al., 1996; Brossier et al., 2004). The mature 735 amino acidPA protein (GenBank accession number AAT98414) contains four distinctfunctional domains (Petosa et al., 1997). Domain 1 (residues 1-258)functions in oligomerization of PA and binding to LF and EF (Chauhan &Bhatnagar, 2002; Cunningham et al., 2002; Lacy et al., 2004), andcontains the sequence ¹⁶⁴RKKR¹⁶⁷, which serves as the furin cleavagesite (Singh et al., 1989; Molloy et al., 1992). Domain 2 (residues259-487) functions in pore formation, heptamerization, membraneinsertion, and translocation of EF and LF (Benson et al., 1998; Milleret al., 1999; Singh et al., 1994). Domain 3 (residues 488-595) functionsin oligomerization (Mogridge et al., 2001), while domain 4 (residue596-735) functions in binding the cellular receptor (Singh et al., 1991;Varughese et al., 1999; Santelli et al., 2004).

Multiple MAbs that target different regions of PA and neutralize LeTx invitro have been previously characterized. Several MAbs target epitopesin domain 4, and neutralize the toxin by preventing PA from binding toits cellular receptor (Little et al., 1988; Little et al., 1996;Brossier et al., 2004). Other MAbs target epitopes in regions spanningthe interfaces between domains 1 and 2 and domains 3 and 4, and preventLF from interacting with PA at the cell surface (Little et al., 1996),or target epitopes in domain 2, preventing cleavage of PA83 to PA63(Brossier et al., 2004). To identify unique neutralizing epitopes in PA,MAbs were raised in mice using whole rPA as the immunogen, and theiraffinities and epitope specificities were characterized.

PCT application WO 02/100340 teaches a vaccine comprising recombinant PAwhich may be combined with LFn, a Lethal Factor deletion which has theC-terminal 47 amino acids removed, thereby eliminating the lethal toxinforming activity.

Published patent application US 2004/0028695 teaches an expressionvector for a “27 kDa N-terminal PA deletion mutant PA27. This mutantcontains amino acid 498-735 of PA and the purpose of this mutant is tocreate a smallest PA deletion mutant to be used as an effectiveantigen.” In one embodiment of the invention, a fusion proteincomprising the N-terminal domain 1 of LF and the C-terminal domains 3and 4 of PA are fused, with domain 3 of PA acting as “a spacer region .. . to keep the correct folding structures of the other two domains fromLF and PA”.

These vaccines are based on the observation that the protective efficacyof PA is greatly increased if small quantities of LF or EF areincorporated into the vaccine (Pezard et al., 1995, Infect. Immun. 63:1369-1372). However, it is believed that this also happens to be theprimary cause of toxigenicity and reactogenicity of the vaccines.

Published patent application US 2004/0009945 teaches an anthrax vaccinewherein the PA coding sequence is inserted into a VEE virus vector inplace of VEE virus structural genes.

PCT application WO 03/048390 teaches an anthrax vaccine which comprisesPA, LF and EF together wherein these proteins have been renderednon-toxic by introducing mutations which affect the biological activityof the proteins without affecting their structure or immunogenicity.

Clearly, there remains a need for an anthrax vaccine which has awell-defined composition and has minimal, if any, side effects.

SUMMARY OF THE INVENTION

According to a first aspect of the invention, there is provided ananti-Bacillus anthracis antibody comprising an amino acid sequence asset forth in any one of SEQ ID No. 10, 12, 14, 16, 18 or 20.

According to a second aspect of the invention, there is provided apharmaceutical composition comprising an antibody as described above anda suitable excipient.

According to a fourth aspect of the invention, there is provided apharmaceutical composition comprising a chimeric antibody as describedabove and a suitable excipient.

According to a fifth aspect of the invention, there is provided aBacillus anthracis neutralizing monoclonal antibody selected from thegroup consisting of F20G75, F20G76 and F20G77.

According to a sixth aspect of the invention, there is provided apharmaceutical composition comprising a Bacillus anthracis neutralizingmonoclonal antibody selected from the group consisting of F20G75,F20G76, F20G77 and combinations thereof and a suitable excipient.

According to a seventh aspect of the invention, there is provided amethod of preventing toxicity associated with the toxins of Bacillusanthracis toxicity in an individual comprising administering to saidindividual an effective amount of a pharmaceutical compositioncomprising a Bacillus anthracis neutralizing monoclonal antibodyselected from the group consisting of F20G75, F20G76, F20G77 andcombinations thereof and a suitable excipient According to an eighthaspect of the invention method of preventing toxicity associated withthe toxins of Bacillus anthracis toxicity in an individual comprisingadministering to said individual an effective amount of a pharmaceuticalcomposition as described above.

According to a ninth aspect of the invention, there is provided anisolated peptide comprising at least 6 consecutive amino acids of anyone of SEQ ID No. 1-9.

BRIEF DESCRIPTION OF THE FIGURES AND TABLES

FIG. 1. Western immunoblot analysis probing specificity and MAbreactivity for rPA. Samples of 2 μg of protein were heat denatured andsubjected to SDS-PAGE, followed by electrophoretic transfer tonitrocellulose membranes. The blots were probed with MAbs F20G75,F20G76, or F20G77, as indicated below each panel. Lane 1, rPA; lane 2,rLF; lane 3, BSA. Protein size markers (kDa) are shown on the left ofthe figure.

FIG. 2. PA domain 2 peptide sequences recognized by MAbs F20G75, F20G76,and F20G77, as determined by pin-peptide epitope mapping (described inSection 2). Amino acid numbering is taken from the mature PA protein(GenBank accession number AAT98414). Residues common to all threepeptides are in bold text.

FIG. 3. Western immunoblot analysis probing MAb reactivity with trypsinand chymotrypsin digests of rPA. Samples of 2 μg of rPA were subjectedto digestion by 40 ng of trypsin or chymotrypsin for 10 minutes on ice,followed by the addition of inhibitor. The digests, and samples of 2 μgof undigested rPA, were then heat denatured and subjected to SDS-PAGEfollowed by electrophoretic transfer to nitrocellulose membranes. Theblots were probed with MAbs F20G75 (A), F20G76 (B), or F20G77 (C). Lane1: rPA, lane 2: BSA, lane 3: trypsin digested rPA, lane 4: chymotrypsindigested rPA. To confirm that chymotrypsin digestion was effective, thesame blots were washed and then re-probed with PA-specific rabbitpolyclonal antiserum. A representative example of chymotrypsin digestedrPA probed with this antiserum is shown in panel D. Size markers (kDa)are shown on the left of the figure.

FIG. 4. Pin-peptide epitope mapping to determine critical residues inthe epitope extending from N306 to V320 in rPA. Synthetic peptides on asolid support matrix were synthesized such that every residue extendingfrom N306 to V320 was altered in turn to Ala (or Gly in the case wherean Ala was already present in the epitope) and their reactivities withMAbs F20G75, F20G76, and F20G77 were assessed via ELISA. The backgroundOD405 value was determined from reactivity of the MAbs with unrelatedpeptide sequences present on the same pin-peptide block. The OD readingfor MAb binding to the “wild-type” peptide (no changes to any amino acidwithin the epitope) was considered the baseline maximum binding level,to which the OD readings for MAbs binding to the altered peptides werecompared as an indication of binding efficiency (% maximum OD=(OD ofaltered peptide/OD of unaltered peptide)×100). The assay was performedtwice for each MAb, and the average value of two experiments is plottedin the graph.

Table 1. Endpoint ELISA titres and affinity of the rPA-specific MAbs.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which the invention belongs. Although any methods andmaterials similar or equivalent to those described herein can be used inthe practice or testing of the present invention, the preferred methodsand materials are now described. All publications mentioned hereunderare incorporated herein by reference.

Described herein is the characterization and isolation of a number ofanti-PA monoclonal antibodies that also have neutralizing activities.Specifically, the monoclonal antibodies are designated as F20G75 (lightchain nucleotide sequence is SEQ ID No. 9, light chain amino acidsequence is SEQ ID No. 10; heavy chain nucleotide sequence is SEQ ID No.15, heavy chain amino acid sequence is SEQ ID No. 16), F20G76 (lightchain nucleotide sequence is SEQ ID No. 11, light chain amino acidsequence is SEQ ID No. 12; heavy chain nucleotide sequence is SEQ ID No.17, heavy chain amino acid sequence is SEQ ID No. 18), and F20G77 (lightchain nucleotide sequence is SEQ ID No. 13, light chain amino acidsequence is SEQ ID No. 14; heavy chain nucleotide sequence is SEQ ID No.19, heavy chain amino acid sequence is SEQ ID No. 20).

Specifically, as will be appreciated by one of skill in the art, theamino acid sequences described above correspond to the variable regionsof the monoclonal antibodies. Accordingly, in some embodiments of theinvention, there are provided chimeric antibodies comprising an aminoacid sequence as set forth in SEQ ID 10, 12 or 14 (F20G75, F20G76 andF20G77 light chain variable region respectively) or chimer antibodiescomprising an amino acid sequence as set forth in SEQ ID No. 16, 18 or20 (F20G75, F20G76 and F20G77 heavy chain variable region respectively).As will be appreciated by one of skill in the art, may be combined forexample fused either chemically or genetically to corresponding humanconstant regions, for example, human IgG1 and IgG2.

In a preferred embodiment of the invention, there are provided chimericantibodies comprising a light chain amino acid sequence as set forth inSEQ ID 10, 12 or 14 (F20G75, F20G76 and F20G77 light chain variableregion respectively) and a heavy chain amino acid sequence as set forthin SEQ ID No. 16, 18 or 20 (F20G75, F20G76 and F20G77 heavy chainvariable region respectively). As will be appreciated by one of skill inthe art, may be combined for example fused either chemically orgenetically to corresponding human constant regions, for example, humanIgG1 and IgG2.

In a further preferred embodiment of the invention, there are providedchimeric antibodies comprising a light chain amino acid sequence as setforth in SEQ ID 10 and a heavy chain amino acid sequence as set forth inSEQ ID No. 16 (light and heavy variable regions from F20G72); a lightchain amino acid sequence as set forth in SEQ ID No. 12 and a heavychain amino acid sequence as set forth in SEQ ID No. 18 (F20G76 lightand heavy chains variable regions); or a light chain amino acid sequenceas set forth in SEQ ID No. 14 and a heavy chain amino acid sequence asset forth in SEQ ID No. 20 (F20G77 light and heavy chain variableregions) As will be appreciated by one of skill in the art, may becombined for example fused either chemically or genetically tocorresponding human constant regions, for example, human IgG1 and IgG2.

As will be appreciated by one of skill in the art, the monoclonalantibodies or chimeric antibodies prepared as described above, eitherindividually or in any various combination may be used as apharmaceutical composition for treating individuals suspected of or atrisk of or having a Bacillus anthracis infection when combined with asuitable excipient as known in the art and as discussed herein.

In other embodiments, an antibody selected from the group consisting ofF20G75, F20G76, F20G77 and humanized or chimeric antibodies derivedtherefrom as described above are used, for example, as a standard, toscreen a sample, for example, human sera samples for the presence ofBacillus anthracis or serum antibodies specific for Bacillus anthracis.As will be appreciated by one of skill in the art, the use of antibodiesto detect the presence of antigenic determinants within a sample iswell-established and may be done by a variety of means. In generalhowever, the process involves the incubation of a sample of interestwith an antibody selected from the group consisting of F20G75, F20G76,F20G77 and humanized or chimeric antibodies derived therefrom asdescribed above under conditions suitable for antibody-antigeninteractions; and detecting if an antibody-antigen interaction hasoccurred.

Suitable conditions may include for example incubation at a temperaturewithin a certain range for a certain period of time in the presence ofadditional chemicals that either promote specific binding or impairnon-specific binding. Such conditions are well known to one of skill inthe art. It is further noted that means for detecting antibody bindingare numerous and are well known in the art.

As will be appreciated by one of skill in the art, the nucleotidesequences encoding the light chains and/or heavy chains of F20G75,F20G76 and/or F20G77 may be operably linked to a suitable promoter suchas a known promoter typically used in a suitable expression system forexpression of the F20G75 light chain (SEQ ID No. 10) or heavy chain (SEQID No. 16), the F20G76 light chain (SEQ ID No. 12) or heavy chain (SEQID No. 18) or the F20G77 light chain (SEQ ID No. 14) or heavy chain (SEQID No. 20). Alternatively, nucleotide sequences deduced from thecorresponding amino acid sequences may be used or the peptides may besynthesized artificially.

In other embodiments, the light chains and/or heavy chains as describedabove are used in the manufacture of humanized or chimeric antibodiesusing means known in the art. As is known to one of skill in the art,this process involves replacement of the non-human immunoglobulinsequences with human sequences, thereby increasing tolerance of theantibody(s) by a human immune system. Accordingly, in some embodimentsof the invention, there is provided a method of generating a humanizedor chimeric anti-Anthrax antibody comprising providing

As discussed below, the above-described monoclonal antibodies bind to aspecific region comprising amino acids 311-316 of PA, ASFFDI (SEQ ID NO:2) or a larger fragment comprising amino acids 301-330 of PA,

SEVHGNAEVHASFFDIGSSVSAGFSNSNSS. (SEQ ID NO. 1)

As will be appreciated by one of skill in the art, vaccines comprisingor consisting of at least 6, at least 7, at least 8, at least 9, atleast 10, at least 11 or at least 12 consecutive amino acids of

SEVHGNAEVHASFFDIGSSVSAGFSNSNSS (SEQ ID No. 1) orSEVHGNAEVAASFFDIGSSVSAGFSNSNSS (SEQ ID No. 3) orSEVHGNAEVHASEEDIGSSVSAGFSNSNSS (SEQ ID No. 4) orSEVHGNAEVAASEEDIGSSVSAGFSNSNSS, (SEQ ID No. 5)or a peptide comprising or consisting of ASFFDI (SEQ ID No. 2) or ASEEDI(SEQ ID No. 6) may be used to immunize individuals at risk of Bacillusanthracis infection or individuals in need of or desirous ofimmunization against a Bacillus anthracis infection. Such individualsinclude for example military personnel or others at risk or believed tobe at risk of encountering Bacillus anthracis. As will be appreciated byone of skill in the art, a vaccine comprising the above-describedpeptides may be prepared by a variety of means known in the art. Forexample, peptides comprising or consisting of SEQ ID NO. 1-6 or variantsor fragments thereof may be prepared recombinantly, for example, inbacterial, yeast or baculovirus systems, and purified. In theseembodiments, the above-described peptides may be encoded by a cDNAinserted into an appropriate expression vector. In some embodiments, theexpression vector may include flanking sequence(s) on either or bothsides of the cDNA, which may or may not be native PA sequences. In someembodiments, the cDNA may be embedded within or genetically linked to asuitable carrier protein. These also include fragment(s) of PA expressedby recombinant DNA methods in vitro or in vivo by genetic recombination.

In preferred embodiments, the above described peptides may besynthesized in vitro. These synthetic peptides may be used alone or maybe cross-linked or otherwise attached to a suitable carrier protein,thereby producing a fusion protein or recombinant protein, as discussedbelow. As will be appreciated by one of skill in the art, a significantadvantage of the synthetic peptides is that they are in a highlypurified form, thereby reducing the risk of side-effects relative tocurrent anthrax vaccines, as discussed above.

It is of note that the use of synthetic peptides or fragments of PAcomprising at least 6 consecutive amino acids of SEQ ID No. 1-6 or avariant thereof differs from the use of full-length PA or mutated PA inthat by exposing the immune system to this specific epitope, theproportion of neutralizing antibodies produced is much greater comparedto use of full-length PA as the antigen. As such, in preferredembodiments, the vaccine may comprise a peptide having at least 6consecutive amino acids of an amino acid sequence as set forth in anyone of SEQ ID No. 1-6 or a variant thereof. As discussed below, thepeptides may be administered to individuals at risk of contactingBacillus anthracis or in need of or desirous of immunization against aBacillus anthracis infection in combination with other compounds knownin the art of vaccine manufacturing. As discussed above, such peptidesmay be used in the formation of recombinant or fusion proteins.

It is of note that as discussed herein, the above-described neutralizingantibody or humanized variant thereof, or of other monoclonal antibodieswhich have similar peptide epitope sub-specificity, may be formulatedinto a pharmaceutical treatment for providing passive immunity forindividuals suspected of or at risk of Bacillus anthracis infectioncomprising a therapeutically effective amount of said antibody. Thepharmaceutical preparation may include a suitable excipient or carrier.See, for example, Remington: The Science and Practice of Pharmacy, 1995,Gennaro ed. As will be apparent to one knowledgeable in the art, thetotal dosage will vary according to the weight, health and circumstancesof the individual as well as the efficacy of the antibody.

Pharmaceutical compositions comprising the neutralizing monoclonalantibodies F20G75, F20G76, F20G77 or humanized or chimeric antibodiesbased on or derived from at least one of the F20G75, F20G76 or F20G77heavy or light variable chains as set forth in SEQ ID Nos. 10, 12, 14,16, 18 or 20 as described above or combinations thereof may beadministered in an effective amount to individuals who have been exposedto or are believed to have been exposed to or are at risk of having beenexposed to or at risk of being exposed to Bacillus anthracis.Administration of these pharmaceutical compositions will accomplish atleast one of the following: slowing disease progression, alleviation ofassociated symptoms and improved predicted medical outcome.

In other embodiments, there is provided a Bacillus anthracis toxinantagonist treatment comprising a peptide made of at least 6 consecutiveamino acids of the epitopes identified by mapping said monoclonalantibodies from in-house and USAMRIID sources, discussed herein. As willbe appreciated by one of skill in the art, the peptides comprising atleast 6, or at least 7, or at least 8 consecutive amino acids of theseepitopes will act to inhibit at least one of the following: toxinfunction, subunit interaction, processing to maturation and bindinginteractions. As will be apparent to one of skill in the art, suchpeptides include at least 6, or at least 7, or at least 8 consecutiveamino acids of SEVHGNAEVHASFFDIGGSVSAGFSNSNSS (SEQ ID No. 7) or maycomprise or consist of ASFFDI (SEQ ID No. 2) or at least 6 or at least 7or at least 8 consecutive amino acids from the sequenceNAEVHASFFDIGGSVSAGFS (SEQ ID No. 8). In other embodiments, thesepeptides include at least 6, at least 7 or at least 8 consecutive aminoacids from any one of SEQ ID No. 1, 3, 4, 5 or 7 or may consist orcomprise of an amino acid sequence as set forth in SEQ ID Nos. 2 or 6 orvariants thereof.

It is of note that It is well known in the art that some modificationsand changes can be made in the structure of a polypeptide withoutsubstantially altering the biological function of that peptide, toobtain a biologically equivalent polypeptide. In one aspect of theinvention, the above-described peptides may include peptides that differby tolerated amino acid substitutions. The peptides of the presentinvention also extend to biologically equivalent peptides that differ bytolerated amino acid substitutions. As used herein, the term “toleratedamino acid substitutions” refers to the substitution of one amino acidfor another at a given location in the peptide, where the substitutioncan be made without substantial loss of the relevant function, in thiscase, the folding of the epitope. In making such changes, substitutionsof like amino acid residues can be made on the basis of relativesimilarity of side-chain substituents, for example, their size, charge,hydrophobicity, hydrophilicity, and the like, and such substitutions maybe assayed for their effect on the function of the peptide by routinetesting. As discussed herein, a His to Ala mutation, which is not aconservative amino acid substitution, improved monoclonal antibodybinding. Similarly, the FF to EE substitution improved peptidesolubility as discussed herein.

In some embodiments, conserved amino acid substitutions may be madewhere an amino acid residue is substituted for another having a similarhydrophilicity value (e.g., within a value of plus or minus 2.0), wherethe following may be an amino acid having a hydropathic index of about−1.6 such as Tyr (−1.3) or Pro (−1.6)s are assigned to amino acidresidues (as detailed in U.S. Pat. No. 4,554,101, incorporated herein byreference): Arg (+3.0); Lys (+3.0); Asp (+3.0); Glu (+3.0); Ser (+0.3);Asn (+0.2); Gln (+0.2); Gly (O); Pro (−0.5); Thr (−0.4); Ala (−0.5); His(−0.5); Cys (−1.0); Met (−1.3); Val (−1.5); Leu (−1.8); Ile (−1.8); Tyr(−2.3); Phe (−2.5); and Trp (−3.4).

In alternative embodiments, conserved amino acid substitutions may bemade where an amino acid residue is substituted for another having asimilar hydropathic index (e.g., within a value of plus or minus 2.0).In such embodiments, each amino acid residue may be assigned ahydropathic index on the basis of its hydrophobicity and chargecharacteristics, as follows: Ile (+4.5); Val (+4.2); Leu (+3.8); Phe(+2.8); Cys (+2.5); Met (+1.9); Ala (+1.8); Gly (−0.4); Thr (−0.7); Ser(−0.8); Trp (−0.9); Tyr (−1.3); Pro (−1.6); His (−3.2); Glu (−3.5); Gln(−3.5); Asp (−3.5); Asn (−3.5); Lys (−3.9); and Arg (−4.5).

In alternative embodiments, conserved amino acid substitutions may bemade where an amino acid residue is substituted for another in the sameclass, where the amino acids are divided into non-polar, acidic, basicand neutral classes, as follows: non-polar: Ala, Val, Len, Ile, Phe,Trp, Pro, Met; acidic: Asp, Glu; basic: Lys, Arg, His; neutral: Gly,Ser, Thr, Cys, Asn, Gln, Tyr. In alternative embodiments, non-conservedamino acid substitutions may be made where an amino acid residue issubstituted for another in a different class, where the amino acids aredivided into non-polar, acidic, basic and neutral classes, as follows:non-polar: Ala, Val, Leu, Ile, Phe, Trp, Pro, Met; acidic: Asp, Glu;basic: Lys, Arg, His; neutral: Gly, Ser, Thr, Cys, Asn, Gln, Tyr. As anexample, simply for illustrative purposes and without limiting theinvention, a change from His (basic) to Ala (non-polar) or Phe(non-polar) to Glu (acidic) are non-conservative changes.

In summary, using both in-house produced toxin-neutralizing monoclonalantibodies as well as toxin-neutralizing monoclonal antibodies obtainedfrom collaborator(s), we have identified the important epitopesrecognized by these toxin-neutralizing monoclonal antibodies.

Based on these potential protective epitope(s) identified by us, newer,better, and well defined subunit anthrax vaccine(s) can be developed forproviding individuals with active protection. The objective of thesenewer subunit vaccine(s) is better immunogenicity as well as lessreactogenicity, that is, fewer side effects.

The toxin-neutralizing antibodies may be developed into therapeutics forpassive protection.

Synthetic peptides may also indirectly inhibit toxin function and hencemay have therapeutic potential. Accordingly, in some embodiments,synthetic peptide vaccines as discussed above are prepared incombination with suitable adjuvants, carrier particles or chemicals,and/or immuno-modulators to booster immune response to the peptides.

Suitable carrier proteins include but are by no means limited to tetanustoxoid, mutant diphtheria toxin, KLH, cholera toxoid or mutant choleratoxin and common plant proteins.

As will be appreciated by one of skill in the art, other suitableadjuvants, such as, for example, but by no means limited to-aluminum orcalcium-based compounds such as aluminum hydroxide and calcium oraluminum phosphate particles; MF59, QS-21, AS02, Montanide ISA-51,Montanide ISA-720; ISCOMS; Cationic PLG microparticles; Detox (MPL+CWS):MPL™+Mycobacterium phlei cell wall skeleton; MPL™:monophosphoryl lipidA; AGL (RC-529): synthetic acylated mono-saccharide; DC-Chol: lipoidalimmunostimulators able to self organize into liposomes; OM⁷-174; OM⁷Triacyl: lipid A derivative; synthetic triacyl pseudo-depeptide; CpGODN: synthetic oligonucleotides containing immunostimulatory CpG motifs;modified LT and CT; MVA: modified vaccinia virus with relevant inserts;hGM-CSF; hIL-12; hIL-2; or Immudaptin: C3d tandem array (Engers et al.,2003 Vaccine volume 21: pp. 3503-3524); polyacryl starch microparticles(Wikingsson and Sjoholm, 2002 Vaccine volume 20: pp. 3355-3363)

As will be appreciated by one of skill in the art, suitableimmunomodulators include but are by no means limited to: CpGoligodeoxynucleotide or CpG oligodeoxynucleotide encapsulated inliposomes (Aviva et al., 2002 Vaccine volume 20: pp. 3342-3354; Li etal., 2002 Vaccine volume 20: pp. 148-157; Mariotti et al., 2002 Vaccinevolume 20: pp. 2229-2239); α2-macroglobulin (Cianciolo et al., 2002Vaccine volume 20: pp. 554-562); various polysaccharide compounds, forexample, various forms of β glucans, zwitterionic polysaccharides suchas polysaccharide A from the anaerobic bacterium Bacteroides fragilis,mannans, hyaluronic acids (Tzianabos, 2000 Clinical Microbiology Reviewvolume 13: pp. 523-533), and immune cell targeting strategies (Berry, J.D., Licea, A., Popkov, M., Cortez, X., Fuller, R., Elia, M., Kerwin, L.,and C. F. Barbas III. (2003) Rapid monoclonal antibody generation viadendritic cell targeting in vivo. Hybridoma and Hybridomics 22 (1),23-31).

Eleven hybridoma clones expressing high titres of rPA-specific MAbs wereidentified, and all were of the IgG1/k isotype. After assaying all ofthe clones via an initial in vitro LeTx neutralization assay, threehybridoma clones F20G75, F20G76, and F20G77, were chosen for furtherstudy. Sequencing of the expressed V_(H) and V_(L) region cDNAsindicates that these were distinct hybridomas formed by theimmortalisation of B cells with uniquely rearranged V genes (Corbett etal., manuscript in preparation). To determine the nature of the rPAepitopes recognized by the anti-rPA MAbs, Western immunoblots wereperformed in duplicate; a representative immunoblot is shown in FIG. 1.All of the MAbs recognized an approximately 83 kDa protein thatcorresponds to mature rPA, and showed no cross-reactivity with eitherrLF or BSA. Binding to denatured protein suggests that these MAbsrecognize a linear epitope (Cohen et al., 1986). The endpoint ELISAtitre of the neutralizing MAbs specific for rPA (coated at 100 ng/well)was defined by the lowest MAb dilution resulting in a five-fold higherOD reading than the background reading obtained against BSA (Table 1).Specificity was good, with no significant reaction to rLF or BSA.Measurement of the affinity of the MAbs for rPA was performed viasurface plasmon resonance analysis. As shown in Table 1, the K_(D) foreach MAb binding to rPA was in the nM range. The k_(on) value for eachMAb was nearly identical, however F20G77 exhibited a significantly lowerk_(off) rate, which greatly increased its apparent affinity for rPA.

To identify the rPA epitopes recognized by the MAbs, overlappingpin-peptides covering the entire sequence of PA were employed forepitope mapping. Each MAb reacted strongly to the same set of threeoverlapping 15-mers (FIG. 2), extending from S301 to S325. The coremotif common to all three 15-mer peptides is ³¹¹ASFFD³¹⁵. In the crystalstructure of mature PA alone (Petosa et al., 1997), and in complex withreceptor CMG2 (Santelli et al., 2004), the region of the 2β2-2β3 loopextending from H304 to S319, encompassing most of the above notedepitopes of the F20G75176/77 MAbs, remains unresolved due to itsflexibility. Within the PA63 heptamer, this region undergoes structuralrearrangements in the acidified endosome, leading to the production of apredicted extended β-barrel that spans the endosomal membrane (Petosa etal., 1997; Benson et al., 1998; Nassi et al., 2002; Santelli et al.,2004). Indeed, specific residues in the region extending from V303 toD315 (Qa'dan et al., 2005), including F313 and F314 (Singh et al., 1994;Benson et al., 1998) are involved in LF translocation, supporting themodel that the 2β2-2β3 loop is involved in β-barrel formation. The³¹³FFD³¹⁵ site in PA domain 2 is sensitive to chymotrypsin cleavage(Novak et al., 1992; Singh et al., 1994), suggesting that a portion ofthe flexible 2β2-2β3 loop containing these residues is solvent exposedin the PA monomer (Singh et al., 1994). rPA was subjected to digestionby trypsin and chymotrypsin and MAb binding to the proteolytic fragmentswas assayed via Western immunoblot. Trypsin cleaves PA at the ¹⁶⁴RKKR¹⁶⁷sequence in domain 1, resulting in 63 and 20 kDa fragments (Novak etal., 1992), while chymotrypsin cleavage at the ³¹³FFD³¹⁵ sequence indomain 2 results in 47 and 37 kDa fragments (Singh et al., 1994). Asshown in FIG. 3, trypsin cleavage had no effect on MAb recognition ofthe 63 kDa fragment of rPA, while chymotrypsin cleavage completelyabrogated MAb binding, confirming that the epitope of all three MAbsextends across the ³¹³FFD³¹⁵ sequence in domain 2. This observation,coupled with the fact that three MAbs were developed that recognize theflexible 2β2-2β3 loop, lends support to the prediction that this regionis exposed on the surface of PA.

To determine whether any particular residues in the identified PA domain2 epitope were critical for MAb binding, a set of 15-mer pin-peptideswas synthesized such that every residue extending from N306 to V320 waschanged in turn to Ala (or in the case of existing Ala residues, toGly). These peptides were assessed in the same manner as described forthe epitope mapping employing overlapping peptides covering the whole PAsequence. As shown in FIG. 4, alteration of residues extending from A311to D315 reduced MAb binding significantly, with F313A, F314A, and D315Ahaving the most apparent effect. The presence of two bulky, hydrophobicPhe residues in the middle of this epitope likely creates a specificpeptide conformation that is critical for MAb recognition (Alvord, Jr.et al., 1986; Warren et al., 1995). Interestingly, changing H310 to Alaincreased apparent MAb binding efficiency by approximately two-fold. TheH310 residue in the epitope may constrain folding of the peptide viainteraction with F314 or F315 (Yoshida et al., 2000), and, as opposed tothe case of the F314A and F315A replacements, the H310A replacementmight result in an alternate structural peptide conformation that leadsto more efficient MAb binding.

In vitro neutralization assays were employed to quantitatively assay theability of the MAbs to neutralize LeTx. The neutralizing titres weredetermined by the lowest MAb concentration that resulted in an ODreading of at least 90-100% of that of the cell control samples(containing no toxin). Two formats of the same assay were employed. Inthe first, MAbs were co-incubated with rPA and rLF prior to addition ofthe LeTx to the cells, while in the second, rPA was allowed to bind tothe J774A.1 cells prior to addition of MAbs and rLF. Using the firstassay format, the MAbs all neutralized LeTx, exhibiting neutralizingtitres of 12.5 ng ml⁻¹ (F20G75), 11.8 ng ml⁻¹ (F20G76), and 16.0 ng ml⁻¹(F20G77). Another MAb, raised against a non-anthrax protein antigen,served as a negative control, and exhibited no neutralization activity.Interestingly, neutralization did not appear to be dose-responsive(Laffly et al., 2005; Brossier et al., 2004). Rather, neutralizationappeared to be an “all or nothing” event, with the ability of each MAbto neutralize LeTx remaining high at concentrations of 12-16 ng ml⁻¹,until a dramatic decrease occurred once the MAbs were diluted to aconcentration approaching 5-7 ng ml⁻¹. This might be due to a strictlydefined “threshold” concentration of MAb molecules required to bind thespecific epitope in rPA and inhibit LeTx activity. Once this minimalthreshold level of MAb molecules is present in the local environmentwhere PA, LF, and the toxin receptor are present, LeTx activity iscompletely abrogated, and the presence of more MAbs in the environmentcauses no increase in neutralization. Alternatively, the high affinityof the neutralizing MAbs for PA might affect the dose responsiveness ofthe observed in vitro LeTx neutralization. As noted previously, anaffinity enhanced PA-specific neutralizing MAb (K_(D) for PA binding0.33 nM) exhibited a much steeper LeTx neutralization dose responsecurve compared to the parental MAb (K_(D) for PA binding 3.5-3.7 nM)from which it was derived (Mohamed et al., 2005). Similarly, a highaffinity (pM range) PA-specific neutralizing MAb lacking an Fc regionexhibited a steep LeTx neutralization dose response curve, although adifferent cell line was employed in that study (Mabry et al., 2005).Nevertheless, these reports do suggest that higher affinity anti-PA MAbs(or scAbs) can result in characteristically steep LeTx in vitroneutralization dose responsiveness. Using the second assay format, inwhich rPA was allowed to incubate with the J774A.1 macrophage cellsprior to the addition of MAbs and rLF, some neutralization of LeTx wasevident. However, MAb concentrations approaching 1-10 μg ml⁻¹ wererequired for significant levels of neutralization to occur, and in somecases the OD readings in the presence of the MAbs in this second assayformat only approached, but did not exceed, a level of 90% compared tothe no-toxin controls. This observation indicates that neutralizationwas considerably more effective when the MAbs were able to bind to rPAprior to addition of the LeTx to the cells, and suggests that these MAbscannot efficiently bind directly to rPA on the cell surface. Thus, it isprobable that the MAbs do not act by blocking LF binding tosurface-bound PA. In support of this observation, the H304-S319“insertion loop,” which contains the epitope recognized by MAbsF20G75/76/77, is essentially buried between neighbouring monomers in theheptameric prepore (Lacy et al., 2004), which would likely restrict MAbaccess to the epitope.

Several methods of neutralization can be envisaged for MAbs F20G75,F20G76, and F20G77. In one scenario, binding of the MAbs to thepredicted surface exposed epitope within the 2β2-2β3 loop of PA mightresult in regional conformational changes in PA that would preventefficient receptor binding. An examination of the co-crystal structureof PA with CMG2 reveals that key interactions are made between the β3-β4loop of domain 2 and CMG2 (Santelli et al., 2004), and since the 2β2-2β3loop is in close proximity to the β3-β4 loop, binding of MAbs to the2β2-2β3 loop might disrupt PA:receptor binding. Alternatively, bindingof the MAbs to this region might create steric hindrance that eitherdirectly blocks access of PA to its receptor, or, more likely, preventsheptamerization after receptor binding. In this latter scenario, one canreason that MAb binding to the above noted epitope within the 2β2-2β3loop region of PA could prevent the interaction of this domain with itsnearest neighbour in the heptamer by creating a physical barrier tointer-subunit binding. Regardless of which specific mechanism results inLeTx neutralization, it is clear from the data presented herein thatthese MAbs most likely neutralize LeTx at a step prior to theinteraction of PA with its receptor and subsequent heptamer formation onthe cell surface.

The data presented here suggest that domain 2 of PA is an immunogenictarget for the development of LeTx neutralizing MAbs, and that the2β2-2β3 loop of domain 2 in rPA is solvent accessible on the surface ofthe PA monomer. Coincidentally, the importance of amino acid residues³¹²SFFD³¹⁵ within this region was recently confirmed using phage peptidedisplay techniques (Zhang et al., 2006). The observations summarizedherein will aid in the development of immunodiagnostic reagents andsubunit vaccine candidates for the detection and treatment of B.anthracis infection.

While not wishing to be bound to a particular theory, it is believedthat the most likely mechanism of the MAbs is to prevent heptamerizationof the PA63 protein, at least in vitro in solution.

We now know definitively that passive administration of at least F20G77protects Fisher brown rats from challenge with a lethal dose of lethaltoxin.

The invention will now be explained by way of example; however, it is tobe understood that the examples are for illustrative purposes and do notnecessarily limit the invention.

2. Materials and Methods

2.1 Mouse immunization protocol and MAb production. For antibodyproduction, pairs of five to six week old BALB/c mice (Charles River,Wilmington, Mass.) were inoculated (day 1) subcutaneously with 5 μg ofrPA (produced as described in Miller et al., 1999) in phosphate bufferedsaline (PBS; pH 7.2), mixed with an equal volume of Complete Freund'sAdjuvant (Difco, BD Biosciences, Oakville, ON). Subcutaneous boosters of5 μg of rPA in PBS mixed with an equal portion of Incomplete Freund'sAdjuvant (Difco) were performed on days 30, 48, and 63. The mice weregiven a final intraperitoneal boost of 3 μg of rPA in PBS and euthanizedthree days later. The rPA-specific humoral immune response was monitoredvia enzyme linked immunosorbent assays (ELISA) using sera collected fromthe mice during the inoculation protocol, as described in (Berry et al.,2004), except the 96-well ELISA plates (MaxiSorp™, Nalge-NUNC,Rochester, N.Y.) were coated with either rPA or, as a negative control,bovine serum albumin (BSA), both at 100 ng/well. Once sufficientanti-rPA titres were detected (OD₄₀₅ in ELISA at least three-fold abovebackground), the mice were euthanized, and hybridoma production andgrowth proceeded as described (Berry et al., 2004). MAb harvesting,concentration, and isotyping were performed as described previously(Berry et al., 2004). Hybridoma supernatants were screened via the sameELISA to identify clones expressing high titres (OD₄₀₅ in ELISA equal toor greater than that observed in the mouse immune serum) of rPA-specificMAbs. Mouse immune and pre-immune sera (diluted 1:2000 with 0.2% BSA inPBS) served as positive and negative controls, respectively. The MAbswere purified using HiTrap™ Protein G HP columns according to themanufacturer's instructions (Amersham Biosciences, Uppsala, Sweden), thebuffer was exchanged with PBS, and the MAb concentrations weredetermined with a Micro BCA Protein Assay Kit according to themanufacturer's instructions (Pierce, Rockford, Ill.).

For comparison purposes, murine hybridomas producing monoclonalantibodies to anthrax protective antigen were obtained from StephenLittle of the US Army Medical Research Institute of Infectious Diseases(USAMRIID). These hybridomas were grown-up and monoclonal antibodiespurified from each and were tested. These were used as positive controlsfor the development of our own hybridomas.

2.2 In vitro LeTx neutralization assays. Lethal toxin (LeTx)neutralization was tested in vitro using the LeTx-sensitive mousemacrophage cell line J774A.1 (ATCC, Manassas, Va.), essentially asdescribed (Laffly et al., 2005). Briefly, the mouse macrophage adherentcell line J774A.1 was seeded at 10⁵ cells ml⁻¹ into the wells of a96-well culture plate (96 Well Clear Flat Bottom Polystyrene TC-TreatedMicroplate, Corning, N.Y.), and grown overnight in BD Cell™ MAb Medium,Quantum Yield (BD Biosciences, Bedford, Mass.) supplemented with 10%standard FBS (HyClone, Logan, Utah), 1% L-glutamine, and 1×antibiotic-antimycotic solution (Wisent, St. Bruno, QC) at 37° C. in a5% CO₂ atmosphere. After overnight incubation the culture supernatantwas removed from each well in the 96-well culture plate. In a separate96-well ELISA plate, 100 μl aliquots of hybridoma supernatants(undiluted) or MAbs (diluted 1:10 to 1:100,000 in PBS) were added toappropriate wells. Into each test well containing diluted MAbs, 100 μlof a mixture of 2.0 μg ml⁻¹ rPA and 1.0 μg ml⁻¹ rLF (produced asdescribed in Kassam et al., 2005) diluted in PBS, was added. Cellcontrol wells contained PBS only, and did not receive any toxin or MAb,and toxin control wells contained toxin but no MAbs. This ELISA platewas then incubated at 37° C. for one hour. 100 μl aliquots of eachdilution of each MAb containing toxin (or appropriate toxin or cellcontrol) was then transferred from the ELISA plate into the wells of the96-well culture plate containing the adherent J774A.1 cells. This platewas then incubated at 37° C. for 2 hours, whereupon 100 μl of freshgrowth medium and 40 μl of CellTiter 96® AQ_(ueous) One Solution CellProliferation Assay medium (Promega, Madison, Wis.) were added. Thecells were incubated for a further 2-2.5 hours at 37° C. to allow forcolour development, and the plate scanned in an ELISA plate reader at490 nm. In a second assay, appropriately diluted rPA was added to theJ774A.1 cells in the absence of any MAb, and the cells were incubatedfor one hour at 37° C. The MAbs were separately combined with rLF andincubated at 37° C. for one hour, and then applied to the cells to whichthe PA was already added. All component concentrations, dilutions,incubations, and other relevant conditions in this second assay formatwere as outlined above. The lowest MAb dilution that resulted in anOD₄₉₀ reading equal to 90% or greater of the no-toxin control was usedto determine the neutralizing titre. All neutralization assays wereperformed at least in triplicate.

2.3 Endpoint ELISA determinations. rPA, rLF, and BSA were diluted in PBS(pH 7.2) and each was coated at 100 ng/well in 96-well ELISA plates at4° C. overnight. The plates were then blocked with 10% skim milk in PBSfor 90 minutes at 37° C., followed by three washes with 0.9% NaCl/0.05%Tween-20. MAbs were diluted (1:10 to 1:10¹⁰) in 2% BSA/PBS, applied tothe wells, and incubated at 37° C. for 90 minutes. The wells were thenwashed four times, and incubated with the secondary antibody(horseradish peroxidase (HRP) conjugated goat anti-mouse IgG F(ab′)₂,Jackson ImmunoResearch, West Grove, Pa.) diluted 1:5000 in 2% BSA/PBS,at 37° C. for 90 minutes. The wells were washed four times, and thencolour development was monitored for 15 to 60 minutes after the additionof 200 μl of ABTS developing solution (Roche Diagnostics, Indianapolis,Ind.), followed by scanning at 405 nm on an ELISA plate reader. Allendpoint ELISA determinations were performed at least twice.

2.4 SDS-PAGE and Western Immunoblotting. Immunoblots were performedessentially as described in (Berry et al., 2004). Briefly, 2 μg of rPA(or proteolytic digests thereof) were mixed with 10-20 μl of SDS-PAGEloading buffer (Bio-Rad, Hercules, Calif.), boiled for 5 minutes, andelectrophoresed at 200V for one hour on a 4-20% Criterion Precastpolyacrylamide gel (Bio-Rad) followed by electrophoretic transfer tonitrocellulose for one hour at 100 V. Equal amounts of BSA and rLF wereincluded as negative controls. Blocking proceeded for one hour at roomtemperature in blocking buffer (10% skim milk in Tris-bufferedsaline/0.1% Tween-20 (TBST)). MAbs were diluted 1:5000 in blockingbuffer, and applied to the blots overnight at 4° C. The blots werewashed with TBST as described in (Berry et al., 2004), incubated at roomtemperature for one hour with a HRP conjugated goat anti-mouse IgGF(ab′)₂ (Jackson ImmunoResearch, West Grove, Pa.) diluted 1:5000 withblocking buffer, and finally washed as described (Berry et al., 2004).Development was performed using either 4-chloro-1-napthol substrate(Sigma) directly, or ECL Plus™ chemiluminescent detection reagentfollowed by exposure to Hyperfilm™ ECL™ (Amersham Biosciences,Piscataway, N.J.), according to the manufacturers' instructions. Blotsprobed with rabbit serum were treated as described above, except theywere incubated with a 1:5000 dilution of immune serum from rabbitsinoculated with rPA, and the secondary antibody used for detection wasHRP conjugated goat anti-rabbit IgG (Jackson ImmunoResearch). Allimmunoblots were performed in duplicate.

2.5 Pin-peptide epitope mapping. Peptides covering the entire length ofPA were synthesized as 15-mers, overlapping by ten residues, coupled tonylon support pins in a 96-well format (Pepscan Systems, Lelystad, theNetherlands). All manipulations of the pin-peptide assemblies wereperformed by placing the tips of the pins in the wells of ELISA plates(MaxiSorp™, Nalge-NUNC, Rochester, N.Y.), ensuring they were fullysubmerged in the liquid samples. The pins were blocked with 200 μl of 4%BSA/PBS for 2 hours at room temperature, followed by three washes with0.9% NaCl/0.05% Tween 20 buffer. The pins were incubated with the MAbs(diluted to 1:500 or 1:1000 in 2% BSA/PBS) overnight at 4° C., andwashed as described above. Incubation with 100 μl of HRP conjugated goatanti-mouse IgG F(ab′)₂ (Jackson ImmunoResearch) diluted 1:5000 in 2%BSA/PBS proceeded at room temperature for 4 hours, followed by washingas described above. Colour development and scanning was performed asdescribed for the endpoint ELISAs above. The epitope mapping experimentswere performed at least twice for each MAb. The cut off value forpositive binding was set at three times the average background OD₄₀₅value.

2.6 Proteolytic digestion of PA. Trypsin (TPCK treated, from Bovinepancreas, Sigma) was dissolved in 1 mM HCl, and α-Chymotrypsin (TypeVII, TLCK treated, Sigma) was dissolved in 1 mM HCl/10 mM CaCl₂ to makeworking stocks of 5 mg ml⁻¹. Trypsin digests were performed in a totalvolume of 20 μl containing 2 μg of rPA mixed with 40 ng of trypsin. Thedigestion buffer was 100 mM Tris-HCl (pH 8). Chymotrypsin digests wereperformed identically, except the digestion buffer was 100 mM Tris-HCl(pH 8)/10 mM CaCl₂. In both cases, the reactions were incubated on icefor 10 minutes, whereupon 2 μl of a 1 mg ml⁻¹ solution oftrypsin-chymotrypsin inhibitor (from soybean, Sigma) was added to stopthe reactions. All proteolysis experiments were performed in duplicate.

2.7 MAb affinity analysis via surface plasmon resonance. The measurementof the MAbs' affinity for rPA was performed essentially as described(Karlsson et al., 1991; Mabry et al., 2005) using a Biacore 2000instrument (Biacore, Uppsala, Sweden). All solutions were purchased fromBiacore. Briefly, a single flow cell on a CM5 sensor chip was activatedby the addition of 20 μl of a 1:1 mixture of1-ethyl-3(3-dimethylaminopropyl)-carbodiimidehydrochloride:N-hydroxysuccinimide (EDC:NHS). 10 μl of a 2.7 mg ml⁻¹solution of rPA was diluted in sodium-acetate (pH 4), and 20 μl of thissolution was coated on the activated chip. The chip was then blocked bythe addition of 35 μl of ethanolamine-HCl, followed by a wash with 35 μlof 10 mM glycine-HCl (pH 1.5). The anti-PA MAbs were diluted in HBS-Pbuffer to final concentrations ranging from 889 to 2200 nM, and 40 μl ofeach dilution (five dilutions in total for each MAb) were applied inturn to the rPA-coated flow cell. The flow cell surface was regeneratedin between additions of antibody dilutions via a wash with 35 μl of 10mM glycine-HCl (pH 1.5). BIAevaluation 3.2 software was used to measureand plot the k_(on) and k_(off) values directly, which were then used tocalculate the affinity (K_(D)).

Synthetic peptides that represent portions of the anthrax protectiveantigen were synthesized and obtained from United Biochemicals ResearchLtd. (Seattle, Wash., USA). They were conjugated to BSA or KLH {KeyholeLimpet Hemocyanin} using methods and reagents in the Imject MaleimideActivated Immunogen Conjugation kit (Pierce Biotechnology, Inc.,Rockford, Ill., USA) for use as antigen in standard indirect ELISA or asimmunogen for immunization of animals respectively.

Immunization of animals with synthetic peptides conjugated to KLH willbe done according to standard in-house laboratory animal proceduresusing Institute Animal Care Committee approved protocol.

While the preferred embodiments of the invention have been describedabove, it will be recognized and understood that various modificationsmay be made therein, and the appended claims are intended to cover allsuch modifications which may fall within the spirit and scope of theinvention.

REFERENCES

-   Abrami L, Liu S, Cosson P, Leppla S H & van der Goot F G (2003)    Anthrax toxin triggers endocytosis of its receptor via a lipid    raft-mediated clathrin-dependent process. J. Cell Biol. 160:    321-328.-   Abrami L, Reig N, & van der Goot F G (2005) Anthrax toxin: the long    and winding road that leads to the kill. Trends Microbiol. 13:    72-78.-   Adams T, Osborn S, & Rijpkema S (2005) An immuno-diffusion assay to    assess the protective antigen content of anthrax vaccine. Vaccine    23: 4517-4520.-   Alvord E C Jr., Hruby S, Martenson R E, Deibler G E, & Law M    J (1986) Evidence for specific polypeptide chain folding in myelin    basic protein from reactions between fragments of the protein and    monoclonal antibodies. J. Neurochem. 47: 764-771.-   Baillie L, Townend T, Walker N, Eriksson U, & Williamson D (2004)    Characterization of the human immune response to the UK anthrax    vaccine. FEMS Immunol. Med. Microbiol. 42: 267-270.-   Benson E L, Huynh P D, Finkelstein A, & Collier R J (1998)    Identification of residues lining the anthrax protective antigen    channel. Biochemistry 37: 3941-3948.-   Berry J D, Jones S, Drebot M A, et al. (2004) Development and    characterisation of neutralising monoclonal antibody to the    SARS-coronavirus. J. Virol. Methods 120: 87-96.-   Bradley K A, Mogridge J, Mourez M, Collier R J, & Young J A (2001)    Identification of the cellular receptor for anthrax toxin. Nature    414: 225-229.-   Brossier F, Levy M, Landier A, Lafaye P, & Mock M (2004) Functional    analysis of Bacillus anthracis protective antigen by using    neutralizing monoclonal antibodies. Infect. Immun. 72: 6313-6317.-   Chauhan V & Bhatnagar R (2002) Identification of amino acid residues    of anthrax protective antigen involved in binding with lethal    factor. Infect. Immun. 70: 4477-4484.-   Cohen G H, Isola V J, Kuhns J, Berman P W, & Eisenberg R J (1986)    Localization of discontinuous epitopes of herpes simplex virus    glycoprotein D: use of a nondenaturing (“native” gel) system of    polyacrylamide gel electrophoresis coupled with western blotting. J.    Virol. 60: 157-166.-   Cunningham K, Lacy D B, Mogridge J, & Collier R J (2002) Mapping the    lethal factor and edema factor binding sites on oligomeric anthrax    protective antigen. Proc. Natl. Acad. Sci. USA 99: 7049-7053.-   Karlsson R, Michaelsson A, & Mattsson L (1991) Kinetic analysis of    monoclonal antibody-antigen interactions with a new biosensor based    analytical system J. Immunol. Methods 145: 229-240.-   Kassam A, Der S D, & Mogridge J (2005) Differentiation of human    monocytic cell lines confers susceptibility to Bacillus anthracis    lethal toxin. Cell Microbiol. 7: 281-292.-   Lacy D B, Wigelsworth D J, Melnyk R A, Harrison S C, & Collier R    J (2004) Structure of heptameric protective antigen bound to an    anthrax toxin receptor: a role for receptor in pH-dependent pore    formation. Proc. Natl. Acad. Sci. USA 101: 13147-13151.-   Laffly E, Danjou L, Condemine F, Vidal D, Drouet E, Lefranc M P,    Bottex C, & Thullier P (2005) Selection of a macaque Fab with    framework regions like those in humans, high affinity, and ability    to neutralize the protective antigen (PA) of Bacillus anthracis by    binding to the segment of PA between residues 686 and 694.    Antimicrob. Agents Chemother. 49: 3414-3420.-   Leppla S H, Robbins J B, Schneerson R, & Shiloach J (2002)    Development of an improved vaccine for anthrax. J. Clin. Invest 110:    141-144.-   Little S F, Leppla S H, & Cora E (1988) Production and    characterization of monoclonal antibodies to the protective antigen    component of Bacillus anthracis toxin. Infect. Immun. 56: 1807-1813.-   Little S F, Ivins B E, Fellows P F, Pitt M L, Norris S L, & Andrews    G P (2004) Defining a serological correlate of protection in rabbits    for a recombinant anthrax vaccine. Vaccine 22: 422-430.-   Little S F, Novak J M, Lowe J R, Leppla S H, Singh Y, Klimpel K R,    Lidgerding B C, & Friedlander A M (1996) Characterization of lethal    factor binding and cell receptor binding domains of protective    antigen of Bacillus anthracis using monoclonal antibodies.    Microbiology 142: 707-715.-   Liu S & Leppla S H (2003) Cell surface tumor endothelium marker 8    cytoplasmic tail-independent anthrax toxin binding, proteolytic    processing, oligomer formation, and internalization. J. Biol. Chem.    278: 5227-5234.-   Mabry R, Rani M, Geiger R, Hubbard G B, Carrion R, Jr., Brasky K,    Patterson J L, Georgiou G, & Iverson B L (2005) passive protection    against anthrax by using a high-affinity antitoxin antibody fragment    lacking an Fc region. Infect. Immun. 73: 8362-8368.-   Miller C J, Elliott J L, & Collier R J (1999) Anthrax protective    antigen: prepore-to-pore conversion. Biochemistry 38: 10432-10441.-   Miller J, McBride B W, Manchee R J, Moore P, & Baillie L W (1998)    Production and purification of recombinant protective antigen and    protective efficacy against Bacillus anthracis. Lett. Appl.    Microbiol. 26: 56-60.-   Milne J C, Furlong D, Hanna P C, Wall J S, & Collier R J (1994)    Anthrax protective antigen forms oligomers during intoxication of    mammalian cells. J. Biol. Chem. 269: 20607-20612.-   Mogridge J, Mourez M, & Collier R J (2001) Involvement of domain 3    in oligomerization by the protective antigen moiety of anthrax    toxin. J. Bacteriol. 183: 2111-2116.-   Mogridge J, Cunningham K, Lacy D B, Mourez M, & Collier R J (2002)    The lethal and edema factors of anthrax toxin bind only to    oligomeric forms of the protective antigen. Proc. Natl. Acad. Sci.    USA 99: 7045-7048.-   Mohamed N, Clagett M, Li J, Jones S, Pincus S, D'Alia G, Nardone L,    Babin M, Spitalny G, & Casey L (2005) A high-affinity monoclonal    antibody to anthrax protective antigen passively protects rabbits    before and after aerosolized Bacillus anthracis spore challenge.    Infect. Immun. 73: 795-802.-   Molloy S S, Bresnahan P A, Leppla S H, Klimpel K R, & Thomas    G (1992) Human furin is a calcium-dependent serine endoprotease that    recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax    toxin protective antigen. J. Biol. Chem. 267: 16396-16402.-   Nassi S, Collier R J, & Finkelstein A (2002) PA63 channel of anthrax    toxin: an extended beta-barrel Biochemistry 41: 1445-1450.-   Novak J M, Stein M P, Little S F, Leppla S H, & Friedlander A    M (1992) Functional characterization of protease-treated Bacillus    anthracis protective antigen. J. Biol. Chem. 267: 17186-17193.-   Okinaka R T, Cloud K, Hampton O, et al. (1999) Sequence and    organization of pXO1, the large Bacillus anthracis plasmid harboring    the anthrax toxin genes. J. Bacteriol. 181: 6509-6515.-   Petosa C, Collier R J, Klimpel K R, Leppla S H, & Liddington R    C (1997) Crystal structure of the anthrax toxin protective antigen.    Nature 385: 833-838.-   Pitt M L, Little S F, Ivins B E, Fellows P, Barth J, Hewetson J,    Gibbs P, Dertzbaugh M, & Friedlander A M (2001) In vitro correlate    of immunity in a rabbit model of inhalational anthrax. Vaccine 19:    4768-4773.-   Qa'dan M, Christensen K A, Zhang L, Roberts T M, & Collier R    J (2005) Membrane insertion by anthrax protective antigen in    cultured cells Mol. Cell. Biol. 25: 5492-5498.-   Reuveny S, White M D, Adar Y Y, Kafri Y, Altboum Z, Gozes Y, Kobiler    D, Shafferman A, & Velan B (2001) Search for correlates of    protective immunity conferred by anthrax vaccine Infect Immun. 69:    2888-2893.-   Santelli E, Bankston L A, Leppla S H, & Liddington R C (2004)    Crystal structure of a complex between anthrax toxin and its host    cell receptor. Nature 430: 905-908.-   Scobie H M, Rainey G J, Bradley K A, & Young J A (2003) Human    capillary morphogenesis protein 2 functions as an anthrax toxin    receptor. Proc. Natl. Acad. Sci. USA 100: 5170-5174.-   Singh Y, Chaudhary V K, & Leppla S H (1989) A deleted variant of    Bacillus anthracis protective antigen is non-toxic and blocks    anthrax toxin action in vivo. J. Biol. Chem. 264:19103-19107.-   Singh Y, Klimpel K R, Quinn C P, Chaudhary V K, & Leppla S H (1991)    The carboxyl-terminal end of protective antigen is required for    receptor binding and anthrax toxin activity. J. Biol. Chem. 266:    15493-15497.-   Singh Y, Klimpel K R, Arora N, Sharma M, & Leppla S H (1994) The    chymotrypsin-sensitive site, FFD315, in anthrax toxin protective    antigen is required for translocation of lethal factor. J. Biol.    Chem. 269: 29039-29046.-   Turnbull P C, Broster M G, Carman J A, Manchee R J, & Melling    J (1986) Development of antibodies to protective antigen and lethal    factor components of anthrax toxin in humans and guinea pigs and    their relevance to protective immunity. Infect Immun. 52: 356-363.-   Varughese M, Teixeira A V, Liu S, & Leppla S H (1999) Identification    of a receptor-binding region within domain 4 of the protective    antigen component of anthrax toxin. Infect Immun. 67: 1860-1865.-   Warren K G, Catz I, & Steinman L (1995) Fine specificity of the    antibody response to myelin basic protein in the central nervous    system in multiple sclerosis: the minimal B-cell epitope and a model    of its features. Proc. Natl. Acad. Sci. USA 92: 11061-11065.-   Yoshida H, Matsushima N, Kumaki Y, Nakata M, & Hikichi K (2000) NMR    studies of model peptides of PHGGGWGQ repeats within the N-terminus    of prion proteins: a loop conformation with histidine and tryptophan    in close proximity. J. Biochem. (Tokyo) 128: 271-281.-   Zhang J, Xu J, Li G, Dong D, Song X, Guo Q, Zhao J, Fu L, & Chen    W (2006) The 2β2-2β3 loop of anthrax protective antigen contains a    dominant neutralizing epitope. Biochem Biophys Res Commun.    341:1164-71

TABLE 1 Endpoint ELISA titres and affinity of the rPA-specific MAbs.Relevant properties Endpoint ELISA k_(on) for rPA binding k_(off) forrPA binding Affinity (K_(D)) for rPA MAb titre (ng ml⁻¹)^(a) (10³ M⁻¹s⁻¹)^(b) (10⁻⁵ s⁻¹)^(b) binding (nM)^(b) F20G75 20 3.4 ± 0.76 6.9 ± 0.4020.8 ± 4.6 F20G76 20 4.0 ± 1.2  6.8 ± 0.25 18.5 ± 5.9 F20G77 20 3.1 ±0.72 0.14 ± 0.013  0.46 ± 0.14 ^(a)Average of three replicates.^(b)Average of at least three replicates, ± standard deviation.

1. An anti-Bacillus anthracis antibody comprising an amino acid sequence as set forth in any one of SEQ ID No. 10, 12, 14, 16, 18 or
 20. 2. (canceled)
 3. The antibody according to claim 1 wherein the antibody is a chimeric antibody.
 4. (canceled)
 5. A Bacillus anthracis neutralizing monoclonal antibody selected from the group consisting of F20G75, F20G76 and F20G77.
 6. (canceled)
 7. A method of preventing toxicity associated with the toxins of Bacillus anthracis toxicity in an individual comprising administering to said individual an effective amount of a pharmaceutical composition comprising a Bacillus anthracis neutralizing monoclonal antibody selected from the group consisting of F20G75, F20G76, F20G77 and combinations thereof and a suitable excipient
 8. (canceled)
 9. An isolated peptide comprising at least 6 consecutive amino acids of any one of SEQ ID No. 1-9. 